Menu

Bertozzi the Editor

Stanford University biochemist Carolyn Bertozzi discusses her role at the helm of ACS Central Science, a cross-disciplinary, open-access chemistry journal

Jun 1, 2016
The Scientist Staff
Glycan chemist Carolyn Bertozzi discusses her role as journal editor in chief.
Carolyn Bertozzi:  We work at the interface of chemistry and biology, and our mission is to develop chemical tools that allow us to study biological processes in new ways, and this has given us insight into how various diseases work and how we might treat them.  We're very interested in cancer and being able to detect cancer at early stages and identify pathways that we can interrupt that might stop the growth of cancer cells. When ACS first approached me with the idea for ACS Central Science, it immediately resonated with some of the issues that I feel are very important in chemistry and in society.  Our challenge is to create a publishing house that basically collects the most exciting high impact work across both chemistry and allied disciplines and bring it together in a way that's accessible, readable, open, welcoming, inclusive.  That's what we can achieve. Because we have no subscription charges, no author charges, this means people can get into this journal at any time from any place.  The barriers to access have been eliminated, and this is I think a trend that major publishing houses are considering and following.  But, ACS is taking a leadership role. If we can use this journal as a vehicle to elevate the visibility of chemistry as the central science, not just amongst chemists—I think most of us are already in agreement with that—but amongst scientists outside of chemistry, amongst people in the population outside of the sciences. Aand again, this is what open access allows you to do. Even 10 to 15 years ago, there was a misconception of open access journals as a place where people just submit the article that could not get accepted anywhere else.  Nowadays, people understand that open access publishing is a social responsibility. As more scientists start to understand the social responsibility of publishing in open access journals, I think what we'll find is that competition to have one's articles accepted in ACS Central Science becomes quite fierce. Our goal at ACS Central Science is to publish work at the leading edge of discovery in fundamental chemistry, but at the same time, we hope to publish interdisciplinary science that showcases the centrality of chemistry.  We're hoping to get articles that are of broad interest, that are accessible to a broad

Read the full story.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.